Cargando…

Copeptin as a marker of an altered CRH axis in pituitary disease

BACKGROUND: Copeptin (pre-proAVP) secreted in equimolar amounts with vasopressin closely reflects vasopressin release. Copeptin has been shown to subtly mirror stress potentially mediated via corticotrophin-releasing hormone. To further test a potential direct interaction of corticotrophin-releasing...

Descripción completa

Detalles Bibliográficos
Autores principales: Lewandowski, Krzysztof C., Lewiński, Andrzej, Skowrońska-Jóźwiak, Elżbieta, Malicka, Katarzyna, Horzelski, Wojciech, Brabant, Georg
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5573756/
https://www.ncbi.nlm.nih.gov/pubmed/28795329
http://dx.doi.org/10.1007/s12020-017-1366-6
_version_ 1783259704018862080
author Lewandowski, Krzysztof C.
Lewiński, Andrzej
Skowrońska-Jóźwiak, Elżbieta
Malicka, Katarzyna
Horzelski, Wojciech
Brabant, Georg
author_facet Lewandowski, Krzysztof C.
Lewiński, Andrzej
Skowrońska-Jóźwiak, Elżbieta
Malicka, Katarzyna
Horzelski, Wojciech
Brabant, Georg
author_sort Lewandowski, Krzysztof C.
collection PubMed
description BACKGROUND: Copeptin (pre-proAVP) secreted in equimolar amounts with vasopressin closely reflects vasopressin release. Copeptin has been shown to subtly mirror stress potentially mediated via corticotrophin-releasing hormone. To further test a potential direct interaction of corticotrophin-releasing hormone with copeptin release, which could augment vasopressin effects on pituitary function, we investigated copeptin response to corticotrophin-releasing hormone. PATIENTS AND METHODS: Cortisol, adrenocorticotropin and copeptin were measured in 18 healthy controls and 29 subjects with a history of pituitary disease during standard corticotrophin-releasing hormone test. RESULTS: Patients with previous pituitary disease were subdivided in a group passing the test (P1, n = 20) and failing (P2, n = 9). The overall copeptin response was higher in controls than in subjects with pituitary disease (area under the curve, p = 0.04 for P1 + P2) with a maximum increase in controls from 3.84 ± 2.86 to 12.65 ± 24.87 pmol/L at 30 min, p < 0.05. In contrast, both groups of pituitary patients lacked a significant copeptin response to corticotrophin-releasing hormone, and even in P1, where adrenocorticotropin concentrations increased fourfold (mean, 21.48 vs. 91.53 pg/mL, p < 0.01), copeptin did not respond (e.g., 4.35 ± 5.81 vs. 5.36 ± 6.79 pmol/L, at 30 min, p = ns). CONCLUSIONS: Corticotrophin-releasing hormone is able to stimulate copeptin release in healthy controls suggesting a direct interaction of corticotrophin-releasing hormone and vasopressin/vasopressin. Interestingly, this relation is altered already in the group of pituitary patients who pass the standard corticotrophin-releasing hormone test indicating (1) the corticotrophin-releasing hormone–adrenocorticotropin–cortisol response is largely independent from the vasopressin system, but (2) the corticotrophin-releasing hormone–vasopressin interaction reflected by copeptin may be much more sensitive to reveal subtle alterations in the regulation of pituitary function.
format Online
Article
Text
id pubmed-5573756
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-55737562017-09-12 Copeptin as a marker of an altered CRH axis in pituitary disease Lewandowski, Krzysztof C. Lewiński, Andrzej Skowrońska-Jóźwiak, Elżbieta Malicka, Katarzyna Horzelski, Wojciech Brabant, Georg Endocrine Original Article BACKGROUND: Copeptin (pre-proAVP) secreted in equimolar amounts with vasopressin closely reflects vasopressin release. Copeptin has been shown to subtly mirror stress potentially mediated via corticotrophin-releasing hormone. To further test a potential direct interaction of corticotrophin-releasing hormone with copeptin release, which could augment vasopressin effects on pituitary function, we investigated copeptin response to corticotrophin-releasing hormone. PATIENTS AND METHODS: Cortisol, adrenocorticotropin and copeptin were measured in 18 healthy controls and 29 subjects with a history of pituitary disease during standard corticotrophin-releasing hormone test. RESULTS: Patients with previous pituitary disease were subdivided in a group passing the test (P1, n = 20) and failing (P2, n = 9). The overall copeptin response was higher in controls than in subjects with pituitary disease (area under the curve, p = 0.04 for P1 + P2) with a maximum increase in controls from 3.84 ± 2.86 to 12.65 ± 24.87 pmol/L at 30 min, p < 0.05. In contrast, both groups of pituitary patients lacked a significant copeptin response to corticotrophin-releasing hormone, and even in P1, where adrenocorticotropin concentrations increased fourfold (mean, 21.48 vs. 91.53 pg/mL, p < 0.01), copeptin did not respond (e.g., 4.35 ± 5.81 vs. 5.36 ± 6.79 pmol/L, at 30 min, p = ns). CONCLUSIONS: Corticotrophin-releasing hormone is able to stimulate copeptin release in healthy controls suggesting a direct interaction of corticotrophin-releasing hormone and vasopressin/vasopressin. Interestingly, this relation is altered already in the group of pituitary patients who pass the standard corticotrophin-releasing hormone test indicating (1) the corticotrophin-releasing hormone–adrenocorticotropin–cortisol response is largely independent from the vasopressin system, but (2) the corticotrophin-releasing hormone–vasopressin interaction reflected by copeptin may be much more sensitive to reveal subtle alterations in the regulation of pituitary function. Springer US 2017-08-09 2017 /pmc/articles/PMC5573756/ /pubmed/28795329 http://dx.doi.org/10.1007/s12020-017-1366-6 Text en © The Author(s) 2017 This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Original Article
Lewandowski, Krzysztof C.
Lewiński, Andrzej
Skowrońska-Jóźwiak, Elżbieta
Malicka, Katarzyna
Horzelski, Wojciech
Brabant, Georg
Copeptin as a marker of an altered CRH axis in pituitary disease
title Copeptin as a marker of an altered CRH axis in pituitary disease
title_full Copeptin as a marker of an altered CRH axis in pituitary disease
title_fullStr Copeptin as a marker of an altered CRH axis in pituitary disease
title_full_unstemmed Copeptin as a marker of an altered CRH axis in pituitary disease
title_short Copeptin as a marker of an altered CRH axis in pituitary disease
title_sort copeptin as a marker of an altered crh axis in pituitary disease
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5573756/
https://www.ncbi.nlm.nih.gov/pubmed/28795329
http://dx.doi.org/10.1007/s12020-017-1366-6
work_keys_str_mv AT lewandowskikrzysztofc copeptinasamarkerofanalteredcrhaxisinpituitarydisease
AT lewinskiandrzej copeptinasamarkerofanalteredcrhaxisinpituitarydisease
AT skowronskajozwiakelzbieta copeptinasamarkerofanalteredcrhaxisinpituitarydisease
AT malickakatarzyna copeptinasamarkerofanalteredcrhaxisinpituitarydisease
AT horzelskiwojciech copeptinasamarkerofanalteredcrhaxisinpituitarydisease
AT brabantgeorg copeptinasamarkerofanalteredcrhaxisinpituitarydisease